The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis
Open accessAbstract
BACKGROUND: . That idea was tested in this trial. METHODS: of 35% or less of the predicted value to receive nintedanib at a dose of 150 mg twice daily plus sildenafil at a dose of 20 mg three times daily (nintedanib-plus-sildenafil group) or nintedanib at a dose of 150 mg twice daily plus placebo three times daily (nintedanib group) for 24 weeks. The primary end point was the change from baseline in the total score on the St. George's Respiratory Questionnaire (SGRQ) at week 12 (the total score ranges from 0 to 100, with higher scores indicating worse health-related quality of life). Secondary end points included measures of dyspnea and safety. RESULTS: A total of 274 patients underwent randomization. There was no significant difference in the adjusted mean change from baseline in the SGRQ total score at week 12 between the nintedanib-plus-sildenafil group and the nintedanib group (-1.28 points and -0.77 points, respectively; P=0.72). A benefit from sildenafil treatment was not observed with regard to dyspnea as measured with the use of the University of California, San Diego, Shortness of Breath Questionnaire. No new safety signals were observed, as compared with previous trials. CONCLUSIONS: of 35% or less of the predicted value, nintedanib plus sildenafil did not provide a significant benefit as compared with nintedanib alone. No new safety signals were identified with either treatment regimen in this population of patients. (Funded by Boehringer Ingelheim; INSTAGE ClinicalTrials.gov number, NCT02802345 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationGaliè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., Simonneau, G., Peacock, A., Vonk Noordegraaf, A., Beghetti, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.01032-2015 · Cited by 3,172
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Lederer, D. J., & Martinez, F. J. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1705751 · Cited by 2,056
Raghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationMode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citationA Controlled Trial of Sildenafil in Advanced Idiopathic Pulmonary Fibrosis
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002110 · Cited by 634
BUILD-1: A Randomized Placebo-controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Behr, J., Brown, K. K., du Bois, R. M., Lancaster, L., de Andrade, J. A., Stähler, G., Leconte, I., Roux, S., & Raghu, G. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200705-732oc · Cited by 500
Self-citationValidation of a New Dyspnea Measure
Eakin, E. G., Resnikoff, P. M., Prewitt, L. M., Ries, A. L., & Kaplan, R. M. (1998) · Chest · doi:10.1378/chest.113.3.619 · Cited by 422
Hy's law: predicting serious hepatotoxicity
Temple, R. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1211 · Cited by 352
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS
Costabel, U., Inoue, Y., Richeldi, L., Collard, H. R., Tschoepe, I., Stowasser, S., & Azuma, A. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201503-0562oc · Cited by 280
Self-citationMacitentan for the treatment of idiopathic pulmonary fibrosis: the randomised controlled MUSIC trial
Raghu, G., Million-Rousseau, R., Morganti, A., Perchenet, L., Behr, J., & the MUSIC Study Group (2013) · European Respiratory Journal · doi:10.1183/09031936.00104612 · Cited by 277
Self-citationPulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Patel, N. M., Lederer, D. J., Borczuk, A. C., & Kawut, S. M. (2007) · Chest · doi:10.1378/chest.06-3087 · Cited by 248
Han, M. K., Bach, D. S., Hagan, P. G., Yow, E., Flaherty, K. R., Toews, G. B., Anstrom, K. J., & Martinez, F. J. (2013) · Chest · doi:10.1378/chest.12-1594 · Cited by 227
Self-citationSong, J. W., Song, J., & Kim, D. S. (2008) · Respiratory Medicine · doi:10.1016/j.rmed.2008.11.012 · Cited by 112
Swigris, J. J., Han, M. K., Vij, R., Noth, I., Eisenstein, E. L., Anstrom, K. J., Brown, K. K., & Fairclough, D. L. (2012) · Respiratory Medicine · doi:10.1016/j.rmed.2012.06.018 · Cited by 110
Elevated brain natriuretic peptide predicts mortality in interstitial lung disease
Corte, T. J., Wort, S. J., Gatzoulis, M. Α., Engel, R., Giannakoulas, G. A., Macdonald, P. M., & Wells, A. U. (2010) · European Respiratory Journal · doi:10.1183/09031936.00173509 · Cited by 68
Self-citationSwigris, J. J., Wilson, H., Esser, D., Conoscenti, C., Stansen, W., Leidy, N. K., & Brown, K. K. (2018) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2018-000278 · Cited by 60
Health-related quality of life in idiopathic pulmonary fibrosis
Belkin, A., & Swigris, J. J. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328363f479 · Cited by 58
Rol, N., de Raaf, M. A., Sun, X., Kuiper, V. P., Bós, D. D. S. G., Happé, C. M., Kurakula, K., Dickhoff, C., Thuillet, R., Tu, L., et al. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy186 · Cited by 51
Milara, J., Escrivá, J., Ortiz, J. L., Juan, G., Artigues, E., Morcillo, E. J., & Cortijo, J. (2016) · European Respiratory Journal · doi:10.1183/13993003.01259-2015 · Cited by 43
No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib
Maher, T. M., Flaherty, K. R., Inoue, Y., Richeldi, L., Selman, M., Stansen, W., Stowasser, S., & Wells, A. U. (2016) · doi:10.1183/13993003.congress-2016.oa4959 · Cited by 5
Self-citation
Cited by
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac237 · Cited by 3,975
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
Humbert, M., Kovacs, G., Hoeper, M. M., Badagliacca, R., Berger, R. M. F., Brida, M., Carlsen, J., Coats, A. J. S., Escribano-Subias, P., Ferrari, P., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00879-2022 · Cited by 2,247
Idiopathic pulmonary fibrosis: state of the art for 2023
Podolanczuk, A. J., Thomson, C. C., Remy-Jardin, M., Richeldi, L., Martinez, F. J., Kolb, M., & Raghu, G. (2023) · European Respiratory Journal · doi:10.1183/13993003.00957-2022 · Cited by 359
Self-citationThe therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 265
Metadata
- Authors
- Kolb, M., Raghu, G., Wells, A. U., Behr, J., Richeldi, L., Schinzel, B., Quaresma, M., Stowasser, S., & Martinez, F. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11
- Volume
- 379
- Issue
- 18
- Pages
- 1722-1731
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2890575335
- Cited by
- 264
- References
- 24
- FWCI
- 23.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.